title: [Recommendations for death rattle].
abstract: Noisy breathing during the terminal stages of life (death rattle) is one of the most common and most difficult symptoms to treat. In palliative medicine there are still no accepted guidelines for the treatment of death rattle in the final phase of life. In the first part of this article a description of death rattle is presented and in the second part a systematic literature review gives an insight into the effectiveness of interventions for death rattle. Two databases (Embase and Medline) were searched up to 2010 which identified 134 studies but only 6 met the inclusion criteria (2 cohort and 4 experimental studies) in which scopolamine, glycopyrrolate, butyl scopolamine, atropine and octreotide were tested. There is a lack of conclusive studies which investigated the effectiveness of treatment of death rattle. Furthermore, the identified studies revealed methodical problems. In general non-drug therapy is recommended as first choice. If anticholinergics are considered the selection also depends on whether simultaneous sedation is desired or not. The English full text version of this article will be available in SpringerLink as of November 2012 (under "Supplemental").
authors.affiliation: Klinik für Palliativmedizin, Klinikum der RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. tpastrana@ukaachen.de
authors.forename: T
authors.initials: T
authors.lastname: Pastrana
authors.forename: H
authors.initials: H
authors.lastname: Reineke-Bracke
authors.forename: F
authors.initials: F
authors.lastname: Elsner
mesh_terms: D000403:Airway Resistance / Q000187:drug effects / Q000502:physiology; D001285:Atropine / Q000009:adverse effects / Q000627:therapeutic use*; D002086:Butylscopolammonium Bromide / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006024:Glycopyrrolate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009093:Mucus / Q000502:physiology; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D056888:Patient Positioning; D012135:Respiratory Sounds / Q000187:drug effects* / Q000502:physiology; D012463:Saliva / Q000502:physiology; D012601:Scopolamine / Q000009:adverse effects / Q000627:therapeutic use*; D013396:Suction; D013727:Terminal Care / Q000379:methods* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D002086:Butylscopolammonium Bromide; D001285:Atropine; D012601:Scopolamine; D015282:Octreotide; D006024:Glycopyrrolate